Key result
Anti-HER2 therapy triggers very late-onset acute heart failure after >100 courses.
Why the study?
Very late-onset cancer therapy-related cardiac dysfunction after prolonged anti-HER2 therapy exposure is extremely rare and not well characterized.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Highlights the risk of very late-onset cancer therapy-related cardiac dysfunction even after prolonged tolerance of anti-HER2 therapy, emphasizing the need for long-term cardiac surveillance.
Cancer therapy-related cardiac dysfunction (CTRCD) is a well-recognized complication of anti-HER2 therapy, typically occurring during or shortly after treatment initiation. However, very late-onset CTRCD after prolonged exposure remains extremely rare. We report the case of an 83-year-old woman with HER2-positive metastatic breast cancer who developed acute decompensated heart failure after more than 100 courses of anti-HER2-based therapy. This case highlights the importance of long-term cardiac surveillance even in patients who have tolerated therapy for extended periods without apparent cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Kikuchi et al. (2026) conducted a case report in HER2-positive metastatic breast cancer (n=1). Anti-HER2-based therapy was evaluated on Acute decompensated heart failure (very late-onset CTRCD). An 83-year-old woman developed acute decompensated heart failure due to very late-onset cancer therapy-related cardiac dysfunction after more than 100 courses of anti-HER2-based therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: